AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Research from Duke University yields new data on HIV/AIDS
June 15th, 2009
According to a study from the United States, "The long-term efficacy of once-daily (qd) fosamprenavir (FPV) 1400mg boosted by ritonavir 100mg (FPV/r100) has not been evaluated previously. A 96-week open-label, randomized, multicenter study compared the efficacy/safety of FPV/r100 with FPV 1400mg boosted by ritonavir 200mg qd (FPV/r200), plus abacavir/lamivudine 600mg/300mg qd, in antiretroviral-naive, HIV-infected patients with viral load (VL) >= 1000 copies/ml." "Primary endpoints were proportion of patients achieving VL <400 copies/ml or discontinuing for drug-related reasons. In the intent-to-treat: exposed (ITT-E) population, missing failure (M=F), and...
Source: AIDS Weekly (2009-06-15)
|
